CDER Wants YOU to Tell It How to Improve the Integrated Review; We Have a Few Ideas of Our Own
FDA Law Blog: Biosimilars
SEPTEMBER 24, 2024
These efforts included the adoption of a new review template for the assessment and documentation to be used in reviewing NDAs and BLAs with an overall goal of having a more collaborative inter-disciplinary approach to the process. Before FDA even asked, we had been considering an HPM FDA Law Blog post on this subject.
Let's personalize your content